Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1

Leukemia Research

Volumn 29, Issue 4, 2005, Pages 407-414

  Findling Kagan, Sarah ^a,b   Sivan, Hamutal ^a   Ostrovsky, Olga ^a   Nagler, Arnon ^a   Galski, Hanan ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

KT 5720; Lymphoma; MDR1 gene; Multidrug resistance (MDR); Multidrug resistant protein (MRP); P glycoprotein (Pgp); Verapamil

Indexed keywords

COLCHICINE; COMPLEMENTARY DNA; DACTINOMYCIN; DOXORUBICIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; KT 5720; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; RETROVIRUS VECTOR; VERAPAMIL; VINBLASTINE;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; CANCER PATIENT; CELL FUNCTION; CELL LINEAGE; CONTROLLED STUDY; DRUG EFFICACY; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; INTERMETHOD COMPARISON; LYMPHOMA; LYMPHOMA CELL LINE; MOLECULAR MODEL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; TRANSGENE; UPREGULATION;

EID: 13844255157     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.09.001     Document Type: Article

References (34)

1. M.M. Gottesman, and I. Pastan Biochemistry of multidrug resistance mediated by the multidrug transporter Annu Rev Biochem 62 1993 385
2. W.T. Bellamy P-glycoproteins and multidrug resistance Annu Rev Pharmacol Toxicol 36 1996 161
3. A.H. Schinkel The physiological function of drug-transporting P-glycoproteins Semin Cancer Biol 8 1997 161
4. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, and M.M. Gottesman Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 39 1999 361
5. G. Lehne P-glycoprotein as a drug target in the treatment of multidrug resistant cancer Curr Drug Targets 1 2000 85
6. L.J. Goldstein, H. Galski, A. Fojo, L.J. Goldstein, H. Galski, and A. Fojo Expression of a multidrug resistance gene in human cancer J Natl Cancer Inst 81 1989 116
7. J.C. Leighton, and L.J. Goldstein P-glycoprotein in adult solid tumors. Expression and prognostic significance Hematol Oncol Clin North Am 9 1995 251
8. M. Hirose Biology and modulation of multidrug resistance (MDR) in hematological malignancies Int J Hematol 76 Suppl 2 2002 206
9. P. Sonneveld Multidrug resistance in haematological malignancies J Intern Med 247 2000 521
10. A. Tulpule, A. Sherrod, D. Dharmapala, L.L. Young, B.M. Espina, and M.N. Sanchez Multidrug resistance (MDR-1) expression in AIDS-related lymphomas Leuk Res 26 2002 121
11. J.M. Ford Experimental reversal of P-glycoprotein mediated multidrug resistance by pharmacological chemosensitizers Eur J Cancer 32A 1996 991
12. G.D. Leonard, T. Fojo, and S.E. Bates The role of ABC transporters in clinical practice Oncologist 8 2003 411
13. D. Nielsen, and T. Skovsgaard P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines Biochim Biophys Acta 11 1992 169
14. S.E. Kane, L. Matsumoto, M.Z. Metz, C.A. Donohue, R.G. Lingeman, and S.W. Lin MDR1 bicistronic vectors: analysis of selection stringency, amplified gene expression, and vector stability in cell lines Biochem Pharmacol 62 2001 693
15. W. van de Vrie, R.L. Marquet, G. Stoter, E.A. De Bruijn, and A.M. Eggermont In vivo model systems of P-glycoprotein-mediated multidrug resistance Crit Rev Clin Lab Sci 35 1998 1
16. D.F. Tang-Wai, S. Kajiji, F. DiCapua, D. de Graaf, I.B. Roninson, and P. Gros Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators Biochemistry 34 1995 32
17. I. Pastan, M.M. Gottesman, K. Ueda, E. Lovelace, A.V. Rutherford, and M.C. Willingham A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells Proc Natl Acad Sci USA 85 1998 4486
18. H. Galski, and A. Nagler Novel inhibitors of multidrug resistance (MDR): evaluation studies for future clinical applications Proceedings of the Seventh Annual Meeting of the European Haematology Association June 6-9, 2002, Florence, Italy, Monduzzi Editore 2002 129 133
19. H. Galski, P. Lazarovici, M.M. Gottesman, C. Murakata, Y. Matsuda, and J. Hochman KT-5720 reverses multidrug resistance in variant S49 mouse lymphoma cells transduced with the human MDR1 cDNA and in human multidrug resistant carcinoma cells Eur J Cancer 31 1995 380
20. P. Lazarovici, H. Galski, Y. Matsuda, and J. Hochman KT-5720, anew bacterial alkaloid antibiotic, reverses multidrug resistance (MDR) in lymphoma and carcinoma cells overexpressing MDR1 gene J Nat Toxins 6 1997 19
21. H. Galski, M. Sullivan, M.C. Willingham, K.V. Chin, M.M. Gottesman, and I. Pastan Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia Mol Cell Biol 9 1989 4357
22. S.E. Bates, J-S. Lee, B. Dickstein, M. Spolyar, and A.T. Fojo Differential modulation of P-glycoprotein transport by protein kinase inhibition Biochemistry 32 1993 9156
23. I.B. Roninson From amplification to function: the case of the MDR1 gene Mutat Res 276 1992 151
24. J. Budworth, T.W. Gant, and A. Gescher Co-ordinate loss of protein kinase C and multidrug resistance gene expression in revertant MCF-7/Adr breast carcinoma cells Br J Cancer 75 1997 1330
25. G.K. Chen, N.J. Lacayo, G.E. Duran, Y. Wang, C.D. Bangs, and S. Rea Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma Genes Chromosomes Cancer 34 2002 372
26. D.W. Shen, A. Fojo, J.E. Chin, I.B. Roninson, N. Richert, and I. Pastan Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification Science 232 1986 643
27. V. Noskova, P. Dzubak, G. Kuzmina, A. Ludkova, D. Stehlik, and R. Trojanec In vitro chemoresistance profile and expression/function of MDR associated proteins in resistant cell lines derived from CCRF-CEM, K562, A549 and MDA MB 231 parental cells Neoplasma 49 2002 418
28. A. Harbottle Drug resistance and reversal M. Alison The cancer handbook 2002 Nature publishing group London, New York, Tokyo 1347
29. Z. Zhan, V.A.bn Sandor, E. Gamelin, J. Regis, B. Dickstein, and W. Wilson Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay Blood 89 1997 3795
30. A.R. Yuen, and B.I. Sikic Multidrug resistance in lymphomas J Clin Oncol 12 1994 2453
31. S.V. Ambudkar, C.O. Cardarelli, I. Pashinsky, and W.D. Stein Relation between the turnover number for vinblastine transport and for vinblastine-stimulated hydrolysis by human P-glycoprotein J Biol Chem 272 1997 21160
32. A. Aszalos, K. Thompson, J.J. Yin, and D.D. Ross Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp) Anticancer Res 19 1999 1053
33. A.H. Dantzig, K.L. Law, J. Cao, and J.J. Starling Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic Curr Med Chem 8 2001 39
34. P. Mistry, A.J. Stewart, W. Dangerfield, S. Okiji, C. Liddle, and D. Bootle In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576 Cancer Res 61 2001 749